TNGX Profile
Tango Therapeutics, Inc. is an innovative biotechnology company focused on discovering and developing novel therapeutics for cancer treatment. The company's research is centered on leveraging the concept of synthetic lethality to identify and target vulnerabilities in cancer cells. Tango Therapeutics' lead program is TNG908, a small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5). This drug is being developed to treat cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions, a genetic alteration that creates specific therapeutic targets for this compound.
In addition to TNG908, Tango Therapeutics is advancing other promising programs in its pipeline. One notable candidate is an inhibitor targeting Ubiquitin-specific protease 1 (USP1), which is being developed to address cancers with BRCA1 or BRCA2 mutations. These mutations are known to compromise DNA repair mechanisms, and targeting USP1 may enhance the efficacy of existing treatments. Another significant program focuses on Target 3, which aims to treat cancers with STK11 mutations. These mutations are associated with various malignancies and represent another critical target for novel therapeutic interventions.
Tango Therapeutics has established a strategic collaboration with Gilead Sciences, Inc., a partnership that enhances its ability to discover, develop, and commercialize a diverse pipeline of cancer therapies. This collaboration leverages Gilead’s extensive expertise and resources in drug development, complementing Tango's innovative approach and expanding the reach of its therapeutic candidates. Through this partnership, Tango aims to accelerate the development of its drug candidates and bring new treatment options to patients with difficult-to-treat cancers.
Founded in 2017 and headquartered in Cambridge, Massachusetts, Tango Therapeutics is committed to pioneering advancements in oncology. The company’s focus on synthetic lethality and targeted therapy positions it at the forefront of cancer research and drug development. By addressing specific genetic vulnerabilities in cancer cells, Tango Therapeutics seeks to deliver more effective and personalized treatment options, ultimately improving outcomes for cancer patients worldwide.
|
